Japan Nutritional Supplements Market Analysis.pdf

Japan Nutritional Supplements Market
Analysis
A sample report on

This report presents a strategic analysis of the Japan Nutritional
Supplements Market and a forecast for its development in the
medium and long term. It provides a comprehensive overview of the
market value, dynamics, segmentation, main players, growth and
demand drivers, challenges & future outlook, etc. This is one of the
most comprehensive reports about the Japan Nutritional
Supplements Market, and offers unmatched value, accuracy, and
expert insights.

3
A Sample Report on Japan Nutritional Supplements Market Analysis I Confidential
Report Scope
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2022
Forecast Period 2023-2030
Report Coverage
Market Overview, Revenue Forecast, Market Segmentation, Growth Factors and Trends,
Competitive Landscape, Key Company Profiles, Government Policies, Regulatory Landscape,
Reimbursement Scenario
Quantitative Units Revenue in USD Million/Billion (Mn/Bn)
Research Approach Secondary Research (60%), Primary Research (40%)
Click on the icon to know the detailed methodology

4
Table of Content
CONTENT PG. NO.
1. Nutritional Supplement Overview 08-21
1.1. Overview
1.2. Japan Overview
1.3. Economic Overview: Japan
1.4. Statistics at a Glance: Japan
1.5. Nutritional Supplement Market in Japan
1.6. Healthcare Scenario in Japan
1.7. Health Insurance Coverage: Japan
1.8. Budget of the Government for Public Insurance
1.9. Mergers and Acquisitions
2. Market Size and Forecasting 22-28
2.1. Market size and forecasts (Excel and Methodology)

5
Table of Content
CONTENT PG. NO.
2.2. Market Segmentation
2.2.1. By Type of Delivery Channel
2.2.2. By Type o Supplements
2.2.3. By Dosage Form
2.2.4. By Application
3. Market Dynamics 29-33
3.1. Market Growth Drivers
3.1.1. Japan Nutritional Supplements Market Driver 1
3.2. Market Restraints
3.2.1. Japan Nutritional Supplements Market Restraint 1

6
Table of Content
CONTENT PG. NO.
3.2.2. Japan Nutritional Supplements Market Restraint 2
4. Competitive Landscape 34-43
4.1. Key Company Profile
4.1.1. Otsuka Pharmaceuticals
4.1.2. Company 2
4.1.3. Company 3
4.1.4. Company 4
4.1.5. Company 5
4.1.6. Company 6
4.1.7. Company 7
4.1.8. Company 8
4.1.9. Company 9
4.1.10. Company 10

7
Table of Content
CONTENT PG. NO.
5. Reimbursement Scenario 44-47
5.1. Reimbursement Regulation
6. Methodology & Scope 48-53

Japan Nutritional Supplements Market Analysis
1. Overview

9
1.1 Statistics at a Glance: The Burden of Nutritional Supplements in the World
Overview of Nutritional Supplements ▪ Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪ In this section you will get an
understanding of the topic, which includes
the prevalence of the disease, the
application of medical devices, new
technology, and other details related to the
topic
▪ In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪ Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
735 Mn
people suffering from
undernutrition in 2021,
worldwide
26 %
is the share of vitamins &
dietary supplements in
nutraceuticals market
60%
of consumers worldwide are taking
vitamins (functional food
products) on a daily basis
$291.33 Bn
is global nutraceuticals
market in 2022
45 %
of deaths among children
under 5 years of age are
linked to undernutrition,
worldwide
US
is the leading country in terms
of sales in the global Nutritional
Supplements Market
Illustrative

10
1.1 Statistics at a Glance: The Burden of Nutritional supplements in
the World (continued)
North America
~ Market Size of
$xx Bn
Europe
~Revenue to reach
$xx Bn by 2027 Asia
-Fastest CAGR
Africa
~Market Size of $xx
Bn
Japan Market
~$xx Mn Market
Illustrative

11
1.2 Japan Overview
▪ Please be aware that this sample report is
report
understanding of the demographics of the
country/region, which includes the
population, GDP, healthcare expenditure
and other details related to the topic
interest
125.2 Mn
Population of Japan
in 2022
48.4
Is the median age
in Japan, in 2022
4.4 Tn
Is the Gross
Domestic Product
(GDP) in Japan in
2022
$3273
Per Capita national
health expenditure of
Japan in 2020
Illustrative

12
1.3 Economic Overview: Japan
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
Population of Japan, (2020-2030)
XX
XX
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2023F
GDP of Japan, (2020-2030)
Population Split (2023)
55-64
0-14
15-24
25-54
65+
Male
49%
Female
51%
By Age Group
By Gender
▪ In this section you will get an understanding of the demographics
of the country/region, which includes the population, GDP,
healthcare expenditure and other details related to the topic
▪ In order to obtain access to all of the information that you are
seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will
include data, analysis, trends, and other relevant information
related to the topic or subject matter of interest
Illustrative

13
1.4 Statistics at a Glance: The Burden of Nutritional supplements in Japan
Prevalence of Nutritional supplements
▪ Please be aware that this sample report
is intended to provide you with a brief
analysis that will be presented in the
final report
understanding of the topic, which
includes the prevalence of the disease,
the application of medical devices, new
technology, and other details related to
the topic in Japan
information that you are seeking, you
will need to purchase the final report
detailed, and it will include data,
analysis, trends, and other relevant
information related to the topic or
subject matter of interest
33.2%
of Japanese population has
a well balanced diet almost
every day
9.5%
Of infants have low weight
during birth
60%
of Japanese adults reported
using dietary supplements
in2019
$23.7 Bn
was the Revenue of
Japan nutraceuticals
market in 2022
2.3%
of children under 5 years of
age are affected by
malnutrition
21.4%
Of Japanese population use
vitamin supplements
Illustrative

14
1.5 Healthcare Service Market in Japan
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Japan Healthcare Service Market Forecast, 2022-2030 (in $Bn)
▪ Please be aware that this sample report is intended to provide you with a brief overview of the kind of information and analysis that will be
presented in the final report
▪ In this section you will get an understanding of the overall Nutraceuticals market in Japan, which includes the market size, current trends and
other details related to the topic
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the topic or
Illustrative

15
1.6 Healthcare Scenario in Japan
Healthcare System:
Japan has a mixed healthcare system that combines elements of both public and private healthcare. The Ministry of Health is responsible for
overseeing and regulating the healthcare sector in the country. The system is designed to provide universal healthcare coverage to all Japanese
citizens
Public Healthcare: The public healthcare system in Japan includes a network of government-run hospitals, clinics, and primary healthcare
centers. These facilities provide healthcare services to the general population, with a focus on preventive care, diagnosis, and treatment. Public
healthcare services are funded through general taxation and social security contributions
Health Insurance: In Japan, all residents are required to have health insurance coverage. The government provides public health insurance
through the Social Security Institution (SGK) for employees and their dependents. For individuals who are not eligible for public insurance, there
are options to purchase private health insurance coverage
Private Healthcare: Private healthcare in Japan is widely available and plays a significant role in the country's healthcare system. Private
hospitals and medical facilities offer a range of services and generally provide a higher standard of care compared to public institutions. Many
residents opt for private healthcare, either by purchasing private insurance or paying out-of-pocket for services
Medical Tourism: Japan has gained popularity as a medical tourism destination in recent years. The country offers advanced medical
treatments and procedures at a relatively lower cost compared to many other countries. Istanbul, in particular, is known for its high-quality
healthcare facilities and attracts international patients seeking various medical treatments, including cosmetic surgery, fertility treatments, and
cardiac procedures
Illustrative

16
1.6 Healthcare Scenario: Patient Journey
Presentation Diagnosis Treatment Follow up
A suspected diagnosis is
usually made, based on
physical examination and
detailed patient and family
history
Prenatal screening/
Neonatal screening
Initial Diagnosis
Complete blood count
(evaluate number &
quality of RBCs, Hb &
WBCs)
Imaging (confirm bone
related changes or
respiratory problems)
Bacterial cultures of
blood, sputum, urine,
stool (detect any
infection)
Genetic testing (detect
the type of SCD)
Confirmatory Diagnosis
Prevention and management of
crisis:
• For VOC and Splenic
Sequestration: HU, Endari,
Adakveo, Oxbryta
• For infections: Antibiotics,
Vaccines
Prevention and management of
complications:
• Stroke: Chronic transfusions, HU
• Long term follow-up is required for
patients with SCD
• Annual assessment: CBC and
reticulocyte count, iron status, liver
and renal function tests, urinalysis,
LDH, vitamin D level and
neurocognitive assessment
• ESOD (End Stage Organ Damage)
evaluation starting from age 7
• Yearly Transcranial Doppler test to
determine risk of stroke
Stakeholders
PCP, paediatrician,
neonatologist,
haematologist and genetic
counsellor
PCP, pediatrician, medical geneticist,
hematologist, gynecologist and pathologist
PCP, pediatrician, medical geneticist,
cardiologist, hematologist,
endocrinologist, psychologist and
psychiatrist
PCP, pediatrician, neonatologist,
endocrinologist, cardiologist,
hematologist, orthopedist, psychologist
and psychiatrist
Depending on the organ complications,
the treatment involves different
specialists at different times
Illustrative

17
1.0
18.9
18.4
35.7
2.5
3.5
10.2
54.3
66.0
91.7
8.3
VA and CHAMPVA
Any public plan
TRICARE
Marketplace
Direct-purchase
Employment-based
Any private plan
With health insurance
Uninsured
▪ In 2021, most people (91.7%) had health insurance coverage at some point during 2021 and 8.3 % of people were uninsured for the entire
calendar year
▪ More people had private health insurance (66%) than public coverage (35.7%)
▪ Employer-based insurance was the most common subtype of health insurance in the civilian, noninstitutionalized population (54.3%),
followed direct-purchase insurance (10.2%), TRICARE (2.5%), and VA and CHAMPVA health care (1%)
Coverage Type 2020 2021 Change %
Total 327,521 328,074
Any health plan 299,230 300,887 0.4
Any private plan 217,896 216,366 –0.6
Employment-based 178,737 178,285 –0.2
Direct-purchase 33,869 33,555 –0.1
Marketplace coverage 10,924 11,389 0.1
TRICARE 9,165 8,299 –0.3
Any public plan 112,925 117,095 1.2
58,541 60,226 0.5
58,778 61,940 0.9
VA and CHAMPVA 2,967 3,151 0.1
Uninsured 28,291 27,187 –0.4
% of People by Type of Health Insurance Coverage
(2021)
Number of People By Health Insurance Coverage
Illustrative
1.7 Healthcare Insurance Coverage

18
1.8 Budget of Japan Government for Public Insurance
Proposed Budget By Category
Outlays 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31
In Billions Of Dollars
Public $769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633
Private $458 $521 $571 $582 $616 $645 $674 $698 $734 $768 $801 $837 $6,926
As % Of GDP
Public 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7%
Private 2.2% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.4% 2.5% 2.5% 2.5% 2.5% 2.4%
▪ National Health Expenditures (NHE) grew 2.7% to $4.3 Tn in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪ Public health Insurance spending grew 8.4% to $900.8 Bn in 2021, or 21% of total NHE
▪ Private health insurance spending grew 5.8% to $1,211.4 Bn in 2021, or 28% of total NHE
▪ Out of pocket spending grew 10.4% to $433.2 Bn in 2021, or 10% of total NHE
▪ Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 Bn, or 14% of total NHE
▪ Hospital expenditures grew 4.4% to $1,323.9 Bn in 2021, slower than the 6.2% growth in 2020
▪ Physician and clinical services expenditures grew 5.6% to $864.6 Bn in 2021, slower growth than the 6.6% in 2020
▪ Prescription drug spending increased 7.8% to $378.0 Bn in 2021, faster than the 3.7% growth in 2020
▪ Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health
spending accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative

19
1.9 Mergers and Acquisitions
$6.0
$7.7
$10.5
$16.7
$6.8
$11.7
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
82
112 107 107
89
110
1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022
57% of the total deal volume are done by strategic buyers and the rest 43% are done by financial buyers in 2020
RCM M&A Deal Value Trend ($Bn) RCM M&A Deal Volume Trend
Buyer Composition: Strategic Vs Financial (2020)
59%
41% 41%
59% 58%
42%
61%
39%
$0- $25 $25-$50 $50-$100 $100+
Strategic Buyers
Financial Buyers
Buyer Type by Deal Size
($Mn)
Illustrative

20
Company Name Type
Amount /
Duration
Year Key Pointers
Acquisition
$620 Mn
November,
2023
▪ Ajinomoto, primarily engaged in the production of seasonings and processed
foods, also operates a healthcare division specializing in pharmaceuticals
derived from amino acids
▪ Ajinomoto announced that Forge will collaborate with its Amino Science
platform to develop innovative treatment solutions for rare diseases
Acquisition $425 Mn
November,
2023
▪ Pharmavite, an Otsuka Pharmaceutical subsidiary based in the United
States, purchases Bonafide Health, a supplier of women's health products
▪ Pharmavite is set to broaden its current range in women's health through the
purchase of Bonafide Health. This expansion will complement its existing
lineup, which includes Uqora, an innovative urinary tract health brand, and
Equelle, a supplement containing equol
Latest Deals In Japan
Illustrative
1.9 Mergers and Acquisitions (continued)

21
Company Name Type
Amount /
Duration
Year Key Pointers
Merger March 2023
Merger Jan 2023
Latest Deals In Japan
Illustrative
1.9 Mergers and Acquisitions (continued)

2. Market Size and Forecasting

23
2.1 Market Size and Forecasts (Excel and Methodology)
XX
XX
2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Japan Nutritional Supplements Market Forecast, 2022-2030 (in $Bn)
final report
understanding of the overall Healthcare
Insurance market in Malaysia, which
includes the market size, current trends
and other details related to the topic
Click on the icon to know the
methodology and assumption
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient
(Mn)
2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
Japan Patient Size (Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of Japan Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size (Bn $) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
Japan Market Size (Bn $) 61 74 84 87 91 95 99 106
Illustrative

24
2.2 Snapshot of Nutritional Supplements Market Segmentation
▪ In this section you will get an understanding of the segmentations which will cover the Japan Nutritional Supplements Market
Analysis
▪ In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Type of Delivery Channel
Online
Pharmacies
Supermarket
Type of Supplements
Herbal supplements
Vitamins & Minerals
Proteins and amino acids
Fatty acids
Prebiotics & probiotics
Other types
Dosage form
Tablets
Capsules
Powders
Liquids
Others
Application
General health
Bone & joint health
Energy & weight
management
Immunity
Diabetes
Skin/hair/nails
Other health applications

25
Japan Nutritional Supplements Market Share, By Type of Delivery
Channel (2022)
Pharmacy
Supermarket
online
final report
2.2.1 Market Segmentation: By Type of Delivery Channel
Illustrative

26
Japan Nutritional Supplements Market Share, By Type of
Supplements (2022)
Vitanins &
Minerals
Herbal
Supplements
Protein & amino
acids
Fatty acids
Prebiotics &
Probiotics
Other types
▪ Vitamins & Minerals is a significant
component of the overall Nutritional
Supplements Market in Japan
▪ It has the maximum market share in
with approximately xx%
final report
2.2.2 Market Segmentation: By Type of Supplements
Illustrative

27
Japan Nutritional Supplements Market Share, By Dosage Form
(2022)
Tablets
Capsules
powder
Liquid
Others
2.2.3 Market Segmentation: By Dosage Form
▪ Tablets is a significant component of
the overall Nutritional Supplements
Market in Japan
▪ It has the maximum market share in
final report
Illustrative

28
Japan Nutritional Supplements Market Share, By Application
(2022)
General health
Bone & joint
health
Energy & weight
management
Immunity
Diabetes
Skin/hairs/nails
Other health
applications
2.2.4 Market Segmentation: By Application
▪ General health have the maximum
market share in Japan Nutritional
Supplements Market by Application
final report
Illustrative

3. Market Dynamics

30
3.1 Market growth drivers
▪ Dietary supplement usage is on the rise in Japan, with an estimated
prevalence of about 60% among healthy adults, ranging from 55% to
70% in adult patients, and standing at 32% among college students
▪ Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
▪ In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
2010 2022 2030
3.1.1 Growing healthy life style awareness in Japan as the functional food market saw an 24% increase in 2022
Nutritional supplement usage in Japan
Illustrative

31
3.1 Market growth drivers (continued)
▪ As individuals age, there is a general decrease in nutrient intake from
food. Older people who undergo undernutrition and lack essential
vitamins and minerals become more prone to infections, with an
increased vulnerability to adverse health consequences like the
development of sarcopenia and osteoporosis
▪ Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
▪ In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪ Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
2010 2022 2030
3.1.2 With 30% of its population aged over 65, the significant demographic of elderly individuals in Japan
underscores a heightened need for nutrient supplementation
Percentage of elderly population in
Japan
Illustrative

32
3.1 Market growth drivers (continued)
Interest in fitness & sports activities in
Japan
3.1.3 Increasing enthusiasm for fitness and sports activities has the potential to elevate the demand for nutritional
supplements
▪ Proportion of individuals engaging in sports and physical
activities on a weekly basis has increased from 23.7% in
1992 to 58.5% in 2022
▪ Please be aware that this sample report is intended to
provide you with a brief overview of the kind of information
and analysis that will be presented in the final report
2010 2022 2030
Illustrative

33
3.2 Market restraints
3.2.1 The supplement industry may face challenges due to
strict regulations and compliance requirements for
manufacturers and distributors.
3.2.2 Consumers may be responsive to the cost of nutritional
supplements, influencing their purchasing choices,
particularly in times of economic uncertainty, where a high
price can potentially diminish demand
Our analysis will thoroughly investigate the key restraints that may significantly impact business
operations and growth.
▪ In Japan, the Ministry of Health, Labor, and Welfare oversees
Foods with Health Claims (FHC), the Consumer Affairs Agency
manages the advertising and sale of such products, while local
health authorities monitor food manufacturing. The Food
Sanitation Act (FSA) is the key legislation ensuring food
integrity, and the Food Labelling Act regulates food labeling
▪ Please be aware that this sample report is intended to provide
you with a brief overview of the kind of information and
analysis that will be presented in the final report
▪ 23.3% of Japanese population feel mineral supplements are
expensive
▪ Please be aware that this sample report is intended to provide
you with a brief overview of the kind of information and
analysis that will be presented in the final report
Illustrative

4. Competitive Landscape

35
4.1 Key Company Profile
▪ Here is the list of top 10 companies which
will cover in the final report
▪ Each company will have slides for
o Overview
o Key details
o Offerings
o Name of products
o Recent activities/ Press Coverage
o Distribution and Vendor Partners
o Mergers, Acquisitions and
Collaboration
o Financials
▪ If there are specific companies that you
would like to be included in the report,
please let us know via email
1 Otsuka Pharmaceuticals
3 Ajinomoto
5 Meji
7 Abbott
9 Riken Vitamin
2 Takeda
4 Taisho
6 Bayer
8 Amway
Kikkoman
10
Key Note:

36
4.1.1 Otsuka Pharmaceuticals
Founded in: 1964
HQ: Tokyo, Japan
Type: Public
Revenue: $xx Bn
Website: Link
▪ Otsuka Pharmaceuticals is dedicated to a comprehensive approach
to health and well-being, aiming to provide innovative
pharmaceutical and nutraceutical products in alignment with its
corporate philosophy
▪ The company is involved in the production, distribution, export, and
import of pharmaceuticals, clinical testing equipment, medical
devices, health foods, and cosmetics
Products offered by Otsuka
➢ Nutrition
➢ Soylution
➢ Rehydration
➢ Cosmedics
➢ Pharmaceuticals
Nutritional Supplements provided
Pocari Sweat Ion Water
Nature Made Soyjoy
Beanstalk Oronamin C drink
B240 Tablets Oronine
Nutraceuticals
Products
Recent Activity / Press Coverage
Otsuka has filed a new drug application in Japan for voclosporin for the
treatment of individuals with lupus nephritis
Pharmavite, an Otsuka Pharmaceutical subsidiary based in the United
States, purchases Bonafide Health, a supplier of women's health products
Otsuka Pharmaceutical will be a sponsor for the themed project
"Resonance of Lives" at Expo 2025 in Osaka, Kansai, Japan

37
4.1.1 Otsuka Pharmaceuticals (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
One of the largest pharmaceutical
distributors in the United States, McKesson
has been a long-standing distribution
partner for Roche
Cardinal Health is a Fortune 500 healthcare
services company that provides
pharmaceutical distribution services to
Roche
It is one of the largest drugstore chains in
the United States and Europe, and its
extensive network of retail locations and
distribution centers make it an important
distribution partner for Roche
A leading healthcare services provider in
Asia, Zuellig Pharma is a distribution
partner for Roche in several Asian countries
One of the largest pharmaceutical
wholesalers in Europe, PHOENIX Group
distributes Roche's products in several
European countries
Roche has been working with SAP, a
leading software company, to develop digital
solutions for its healthcare products
A leading Swiss biotechnology company,
Lonza provides Roche with contract
manufacturing services for the production of
its biologics and pharmaceuticals
Roche has a strategic partnership with
Microsoft to leverage its cloud computing
and AI technologies in the development of
new healthcare products
Thermo Fisher Scientific is a leading
provider of analytical instruments, reagents,
and laboratory services
GE Healthcare provides Roche with
advanced medical imaging and diagnostics
technologies, including CT scanners and
MRI machines
Illustrative

38
Company Name Type
Amount /
Duration
Year Key Pointers
Acquisition $425Mn
November,
2023
▪ Pharmavite, an Otsuka Pharmaceutical subsidiary based in the
United States, purchases Bonafide Health, a supplier of women's
health products
▪ Pharmavite is set to broaden its current range in women's health
through the purchase of Bonafide Health. This expansion will
complement its existing lineup, which includes Uqora, an
innovative urinary tract health brand, and Equelle, a supplement
containing equol
Latest Deals - Mergers and Acquisitions
Illustrative

39
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Illustrative

40
4.1.2 Company2
Founded in:
HQ:
Type:
Revenue:
Website:
Solutions offered by Company
Drugs Indications
Drugs for Cancer Recent Activity / Press Coverage
Illustrative

41
4.1.2 Company2 (continued)
Major Distribution Partners Major Vendor Partners
Partnerships Ecosystem
Illustrative

42
Company Name Type
Amount /
Duration
Year Key Pointers
Latest Deals - Mergers and Acquisitions
Illustrative

43
xx xx xx
2020 2021 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Revenues ($Bn), 2020-2030
report
▪ In this section you will the understating of
financial overview of the company, which
includes revenue forecasting, segment
revenue and other key details as per
availability
interest
Breakdown of Net Revenue by Segment, 2022
1 2 3 4
Illustrative

5. Reimbursement Scenario

45
5.1 Reimbursement Regulation
The reimbursement scenario in the Turkey nutraceuticals market is complex and
can vary depending on the specific treatment, setting of care, and insurance
coverage. Here are some key points to consider:
▪ Public Insurance:
o Public Insurance is a federal health insurance program for people aged
65 and older, as well as people with certain disabilities or health
conditions
o However, coverage can be subject to strict guidelines and restrictions,
such as the requirement for prior authorization
▪ Private Insurance:
o Private insurance coverage for cancer Nutraceuticals can also vary
widely depending on the insurer and the specific policy
o Some policies may have high out-of-pocket costs, such as deductibles
and co-pays, while others may have more comprehensive coverage
Public Insurance and private insurance
together provide health insurance
coverage for more than 4 in 10 Japanese
People
public
insurance
41%
Other Private
14%
Other Public
4%
Uninsured
41%
Health Insurance Coverage, 2022
Illustrative

46
5.1 Reimbursement Regulation (continued)
▪ Affordable Care Act:
o Affordable Care Act (ACA) includes provisions to help improve access to Clinical Trials treatments by requiring insurers to
cover certain preventive services, including Clinical Trials screenings, without co-pays or deductibles
o It also includes protections for people with pre-existing conditions, such as Clinical Trials
▪ Reimbursement for New Treatments:
o Reimbursement for new Clinical Trials treatments can be a complex and lengthy process, as insurers and government
programs often require evidence of safety and effectiveness before providing coverage
o This can create challenges for companies developing and marketing new treatments
▪ Value-Based Care:
o There is a growing trend towards value-based care, which aims to improve outcomes and lower costs by focGlobaling on the
value of treatments rather than simply the volume of treatments
o Value-based care models can include payment models that tie reimbursement to outcomes or performance metrics
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest Illustrative

47
5.1 Reimbursement Regulation (continued)
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
Reimbursement Market Trends
 Public healthcare coverage is provided by the government and includes programs like
Medicare and Medicaid
 Medicare is a federal program that provides healthcare coverage to individuals who
are 65 years of age or older, as well as certain younger people with disabilities
 Medicaid is a joint federal-state program that provides healthcare coverage to
individuals with low income and limited resources
▪ Shift towards value-based care has been a significant trend in the US healthcare system, with payers and providers increasingly focused on improving patient
outcomes and reducing costs
▪ This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care 38.9%
37.1%
35.6%
32.5%
31.5%
44.0%
46.0%
47.7%
51.0%
51.8%
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
100% 100% 100% 100% 100%
xx xx xx xx xx
2012 2013 2014 2015 2016
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative

Life-sciences Market Research
Reports you can trust
www.insights10.com
We maintain an extensive database comprising
over 30,000 syndicated market research reports
within the pharmaceuticals and healthcare sector,
offering a global, regional, and country-level
perspective. Our services also include the provision
of customized research reports, meticulously
tailored to align with your specific requirements.

At Insights10, our extensive report
library spans a diverse range of
categories within the field of life
sciences.
Market Research
Reports across various
categories in healthcare
www.insights10.com
Digital
Health
Medical
Devices
Healthcare
Services
Rare
Diseases
Clinical
Trials
OTC &
Nutraceuticals
Pharma
(Diseases
& Drugs)

Click on the country to see the reports
available
Global Coverage
North America
• US
• Canada
Latin America
• Brazil
• Argentina
• Mexico
• Ecuador
• Venezuela
• Senegal
Europe
• UK
• Germany
• France
• Italy
• Spain
• Russia
• Netherlands
• Sweden
• Romania
• Switzerland
• Poland
• Austria
• Ireland
• Norway
• Denmark
• Belgium
• Portugal
• Ukraine
• Bulgaria
• Finland
APAC
• India
• China
• South Korea
• Japan
• Australia
• Indonesia
• Hong Kong
• New Zealand
• Philippines
• Singapore
• Malaysia
• Thailand
• Vietnam
Middle East
• UAE
• Saudi Arabia
• Turkey
• Lebanon
• Kuwait
• Qatar
Africa
• Egypt
• Kenya
• South Africa
• Algeria
• Nigeria
• Libya
• Tanzania
• Morocco

What do our reports cover?
Market Overview
Growth Drivers & Growth Restraints
Epidemiology & Disease type
Market Size & Forecast
Competitive Landscape
Policy & Regulatory Landscape
Reimbursement Scenario
Recent Developments
Market Segmentation Factors Driving Future Growth
1
2
3
4
5
6
7
8
9
10

01 03
02 04 05
Define
precise
research
questions
Validate data
through primary
research
interviews
Gather data
through
secondary
research
Forecast
market size
and segment
analysis
Extract key
insights from
the research
findings
06
Compile &
present a
comprehensive
analytical report
Our Research Process

Bottom Up Approach
Analyze product or treatment pricing
and reimbursement strategies
Evaluate consumer or patient
demographics and numbers
Predict future market
growth or decline based
on key market trends &
dynamics
Find
final
market size
Top Down Approach
Examine the total healthcare expenditure in
the targeted disease or service domain.
Assess the proportion of spending
allocated to the specific product or
treatment category.
Predict future market
growth or decline
based on key market
trends & dynamics
Find
final
market
size
Data Triangulation & Data Validation

2022
2023-
2030
Report Attribute
Quantitative Units
Pricing and Purchase
Revenue in USD Million/Billion (Mn/Bn)
Our pricing and purchase options are adaptable to
suit the specific scope of work.
Details
Time Frame
Base
Year for
estimation
Forecast
Period
Report Scope
Delivery Timeline
Typically, the delivery of the final report falls within a
timeframe of 5 to 7 business days, but the exact
duration may vary depending on the project's scope.
Customization
We are pleased to offer you the option of
customizing the report to align with your specific
research requirements at no extra charge, provided
it falls within the defined scope of the project.

We have access to a multitude of highly
dependable data sources, supported by
years of experience that guide us in
discerning which sources are most reliable
and current for the specific information
needed.
Access to credible
data sources for
secondary research
www.insights10.com
Statistical
Databases
Annual
Reports
Trade
Publications
Online
Databases
Published
Research
Reports
White-
papers
Press
Releases

Reliable
Expert Verified
Realistic
Comprehensive
Easy to read
Our reports present data, which is
The report is prepared using a proven methodology and insightful
research
The report is prepared by a team of highly qualified & experienced
research analysts & vetted by our local associates
The report allows you to confidently make smarter business and
strategic decisions based on realistic findings
Covers everything you would need to know about the market
including market size, competitive analysis & much more
You do not have to be a market expert to understand what really is
happening on the market and how it works

Yearly Access
(Subscription)
Regulatory
Compliance
Competitive
Intelligence
Conference
Coverage
Full-Time
Engagement
Database Service
& KOL Mapping
Primary Research &
Interviews
Customized Market
Research Reports
Syndicated Market
Research Reports
Our Services

“The business decision-making process is no longer as
straightforward as it used to be. It requires insights
generated at the right time, based on reliable data
interpreted in a nuanced manner for each market. We at
Insights10 are building the future of market research and
are committed to providing our clients with the right
intelligence and insights to make business decisions
quickly and efficiently.
Insights10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working with
some of the best organizations in the world, generating
insights that provides substantial competitive advantage.”
Dr. Purav Gandhi, Founder & CEO
Click to watch Our Introductory Video here
CEO Speaks

Purav is a physician and an
entrepreneur with 12+ years of
experience in Healthcare & Life
Sciences industry spanning across
strategy, market access, health
informatics and RWE, digital health,
analytics and data science. Purav
studied medicine from Gujarat
University and also completed his MBA
from IIM-Kozhikode. Purav started his
career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Anish has 15+ years of
experience in management
consulting in the Life Sciences
sector, and has worked with
diverse multinational firms in
the US, India, Middle East and
APAC regions. His primary area
of interest is Customer and
Market Strategy, Market
Access, and Digital Health with
special focus on emerging
markets like Africa, Middle East
and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research &
marketing professional with a
progressive experience of over 20
years in Life Sciences, Healthcare
services, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare &
completed several research projects
across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across
diff. markets (America, Europe, Africa,
APAC and Middle East). Her areas of
expertise include: Indentifying emerging
trends in life sciences industry,
Competitor landscape assessment,
Disease opportunity assessments etc.
She is a pro in secondary and primary
research with a deep domain expertise
in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager
Leadership Team

… and many more
Pi-SM
GmbH
Our Clients

I've had the pleasure of availing Insights10’s services several times, and I've always
been impressed by their expertise, professionalism, and dedication to providing us with
the highest quality data and insights. Whether one is looking to launch a new product,
expand into a new market, or better understand one's target customers, Insights10
insures achieving the goals.
Their team of experts has a deep understanding of the healthcare industry, and they use
their knowledge to develop customized research solutions that meet the specific needs
of each client. I highly recommend Insights10 to anyone looking for a reliable and
experienced partner in healthcare market research. They're a valuable asset to any
company that wants to succeed in this dynamic sector.
Sid Panigrahy
Founder-CEO, MediGlobo Inc.,
(Healthcare - Group Company of Omi Holdings, Inc) Tampa, Florida (USA)
What our clients say

Dear Insights10 Team, I wanted to thank you all for the great work you conducted
producing the Kenya Medical and Diagnostic Laboratory Service Market Analysis. The
quality of the report was excellent, and you managed to complete it in record time. I was
also impressed by your quick turnaround on the topics discussed as a follow up after the
report's first version; you managed to gather the information required, plus a very good
analysis.
I will definitely consider working with you again if the opportunity arises, and will not
hesitate in recommending you to colleagues working in the field Thank you again for
your professionalism and team work. It was a pleasure working with you.
Lelio Marmora
CEO, The Management Lab, Geneva
Ex. Executive Director, UNITAID

Michael Blumberg Youssef Mallat
Wissem Menad
Dr. Robert Ryan
Co Founder GFAU Pty Ltd., Australia
Co Founder – Embi, Optimum Oral care, Australia
Opusline, A part of Accenture, Paris
Senior Manager Segment Marketing
Performance Health, London, UK
Chief Executive Officer, Innova Therapeutics, Inc., USA
We engaged INSIGHTS10 to assist us with our research requirements
for the Oral Care Market sector in Australia. We been very impressed
with the depth and quality of data and equally with the personal
service we experience from the management team on our account.
They understand our business, our challenges and our goals. There is
a real sense of partnership as we continue to work together.
The info you delivered on the European Patient
Support Market with a deep dive into countries
like Spain, Germany, Italy, France, UK and
Belgium, was very useful.
Insights10 has been a great resource for
getting a detailed report on the UK
Physiotherapy Market. Usually I had multiple
sources for getting global reports, but now I
can get in-depth country reports from
Insights10 which has been a game changer.
We were looking for very specific information regarding Abu Dhabi
Oncology Drugs Market. The insights provided by Insights10 is
fantastic and they just took less than three days to deliver the report.

Thank You
www.insights10.com
Email: insights@insights10.com
India: (+91) 931 639 7935
We would be happy to help.
Do you have
any questions?

Japan Nutritional Supplements Market Analysis.pdf

More Related Content

Similar to Japan Nutritional Supplements Market Analysis.pdf

More from Insights10

Recently uploaded

Japan Nutritional Supplements Market Analysis.pdf